Figure 4: Proportion of patients achieving a therapeutic glycemic response (HbA1c <7%) at week 24. Proportion of patients achieving a therapeutic glycemic response. Data collected before receiving rescue medication. The proportion of patients achieving HbA1c was evaluated using ANCOVA model with last observation carried forward to account for missing data. Compared with placebo, saxagliptin 5 mg significantly increased the proportion of patients who achieved HbA1c <7% at week 24 (P<0.0001) and saxagliptin 2.5 mg was associated with a numerical increase. ANCOVA=analysis of covariance; HbA1c= glycated hemoglobin; NS=not significant. *Number of randomized patients with week 24 values.